3-氨基-6-溴-5-甲基吡嗪-2-羧酸甲酯 | 1131-22-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-氨基-6-溴-5-甲基吡嗪-2-羧酸甲酯
• 英文名称: methyl 3-amino-6-bromo-5-methyl-pyrazine-2-carboxylate
• 英文别名: Methyl 3-Amino-5-methyl-6-brompyrazinecarboxylate；3-amino-6-bromo-5-methyl-pyrazine-2-carboxylic acid methyl ester；Methyl 3-amino-6-bromo-5-methylpyrazine-2-carboxylate
• CAS: 1131-22-2
• 化学式: C₇H₈BrN₃O₂
• 分子量: 246.063
• InChiKey: GXNWVJBKCSDFIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  78.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-氨基-6-溴-5-甲基吡嗪-2-羧酸甲酯 在 sodium azide 、 氟化氢吡啶 作用下， 以89 %的产率得到methyl 6-bromo-3-fluoro-5-methyl-pyrazine-2-carboxylate
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER
  [FR] PYRAZINE-2-CARBOXAMIDES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE HPK1 POUR LE TRAITEMENT DU CANCER

  摘要：

  There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoietic progenitor kinase 1 (HPK1) and are thereby particularly useful in the treatment or prophylaxis of cancer.

  公开号：

  WO2023001794A1
• 作为产物：
  描述：

  3-氨基-5-甲基-吡嗪羧酸 在 N-溴代丁二酰亚胺(NBS) 、 硫酸 作用下， 以 乙腈 为溶剂， 反应 17.5h， 生成 3-氨基-6-溴-5-甲基吡嗪-2-羧酸甲酯
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER
  [FR] PYRAZINE-2-CARBOXAMIDES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE HPK1 POUR LE TRAITEMENT DU CANCER

  摘要：

  There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoietic progenitor kinase 1 (HPK1) and are thereby particularly useful in the treatment or prophylaxis of cancer.

  公开号：

  WO2023001794A1

文献信息

• Heterocyclic amines for the treatment of conditions associated with gsk-3
  申请人：——

  公开号：US20040186113A1

  公开（公告）日：2004-09-23

  The present invention relates to new compounds of the formula (I) wherein Y, X, P, Q, R 1 , R 2 , R 3 , R 4 , R 5A , R 6 , R 7 , R 8 , R 9 , A, B, n, m are defined as in claim 1, a process for their preparation, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds for the treatment of conditions associated with glycogen synthase kinase-3 (GSK3) as well as an intermediate used in the preparation of said compounds. 1

  本发明涉及公式（I）的新化合物，其中Y，X，P，Q，R1，R2，R3，R4，R5A，R6，R7，R8，R9，A，B，n，m的定义如权利要求书中所述，以及其制备过程，含有所述治疗活性化合物的制药配方以及所述活性化合物用于治疗与糖原合成酶激酶-3（GSK3）相关的疾病的用途，以及用于制备所述化合物的中间体。
• HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3
  申请人：AstraZeneca AB

  公开号：EP1406877A1

  公开（公告）日：2004-04-14
• [EN] HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3<br/>[FR] AMINES HETEROCYCLIQUES POUR LE TRAITEMENT DE PATHOLOGIE EN RAPPORT AVEC GSK-3
  申请人：ASTRAZENECA AB

  公开号：WO2003004475A1

  公开（公告）日：2003-01-16

  The present invention relates to new compounds of the formula (I) wherein Y, X, P, Q, R1, R2, R3, R4, R5, R6, R7, R8, R9, A, B, n, m are defined as in claim 1, a process for their preparation, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds for the treatment of conditions associated with glycogen synthase kinase-3 (GSK3) as well as an intermediate used in the preparation of said compounds.
• [EN] SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] PYRAZINE-2-CARBOXAMIDES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE HPK1 POUR LE TRAITEMENT DU CANCER
  申请人：[en]ASTRAZENECA AB

  公开号：WO2023001794A1

  公开（公告）日：2023-01-26

  There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoietic progenitor kinase 1 (HPK1) and are thereby particularly useful in the treatment or prophylaxis of cancer.